Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
DelotaSYDRF 18 EBITDA Margin % is 5.64% as of Mar. 2026, which is 133% above its 10-year median of 2.42. GuruFocus rates SYDRF with a GF Score™ of 18/100 and a GF Value™ of $0.14. The stock has 3 warning signs investors should review. Among 665 Healthcare Providers & Services companies, Delota ranks worse than 66.77% on this metric.
EBITDA Margin % is calculated as EBITDA divided by its Revenue. Delota's EBITDA for the
three
months ended in Mar. 2026 was $0.32 Mil. Delota's Revenue for the
three
months ended in Mar. 2026 was $5.61 Mil. Therefore, Delota's EBITDA margin for the quarter that ended in Mar. 2026 was 5.64%.
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
Delota EBITDA Margin % Related Terms
Delota EBITDA Margin % Historical Data
* Premium members only.
The historical data trend for Delota's EBITDA Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Pharmaceutical Retailers subindustry, Delota's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Delota EBITDA Margin % vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, Delota's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where Delota's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Delota (SYDRF) has a EBITDA Margin % of 5.64% as of Mar. 2026. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Delota and its competitors. This is 133% above median its historical median of 2.42. According to the industry distribution chart, Delota ranks #444 out of 665 companies in the Healthcare Providers & Services industry, placing it in the top 66.8%.
Is Delota's EBITDA Margin % too high?
Delota's current EBITDA Margin % of 5.64% is 133% above median its 10-year median of 2.42. The Healthcare Providers & Services industry median EBITDA Margin % is 10.24. Delota's value of 5.64% is 44.9% below this industry median. Based on the distribution chart, Delota ranks #444 out of 665 companies in the Healthcare Providers & Services industry, which is below the industry midpoint. Overall, Delota has a GF Score™ of 18/100, reflecting its overall financial health beyond just this single metric.
How does Delota's EBITDA Margin % compare to competitors?
According to the Healthcare Providers & Services industry distribution chart, Delota ranks #444 out of 665 companies for EBITDA Margin %. This places Delota in the lower half of its industry. The industry median EBITDA Margin % is 10.24. Delota's value of 5.64% is 44.9% below this benchmark. While the company's 10-year median is 2.42 vs. the industry median of 10.24, Delota has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Healthcare Providers & Services company?
The median EBITDA Margin % among Healthcare Providers & Services companies is 10.24, based on 665 companies in the industry. Companies in the top quartile (top 25%) have a EBITDA Margin % significantly above this median, while those in the bottom quartile fall well below. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Delota's current EBITDA Margin % of 5.64% is 44.9% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Delota and its competitors. For the Healthcare Providers & Services industry, the median EBITDA Margin % is 10.24 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Delota's current EBITDA Margin % is 5.64%, which is 133% above median its own 10-year median of 2.42. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Delota stock overvalued right now?
Delota (SYDRF) has a current EBITDA Margin % of 5.64%. The stock's GF Value™ is $0.14, compared to a current price of $0.10 — trading 28.6% below its estimated fair value. The current EBITDA Margin % is 5.64%, which is 133% above median its 10-year median of 2.42 and 44.9% below the Healthcare Providers & Services industry median of 10.24. Delota's overall GF Score™ is 18/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For Delota (SYDRF), the current EBITDA Margin % is 5.64% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Delota (SYDRF) Overvalued in 2026?
Based on GuruFocus' analysis, Delota stock appears to be undervalued.
The current stock price of $0.10 is trading 28.6% below its estimated GF Value™ of $0.14.
Key valuation signals for SYDRF:
EBITDA Margin %: 5.64% (133% above median its 10-year median of 2.42)
GF Value™: $0.14 vs. price of $0.10 (28.6% below fair value)
Industry Position: 44.9% below the Healthcare Providers & Services median (#444 of 665)
No single metric tells the full story. See the SYDRF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Delota Corp is a cannabis and nicotine retailer. The company is engaged in developing retail cannabis and nicotine brands in Canada by growing its retail footprint and developing retail banners. The Company's flagship brand, one hundred eighty Smoke Vape Store, stands as Ontario's omni channel specialty vape retailer, fueling innovation, growth, and leadership in the nicotine vape and alternative tobacco sector. The Company operates twenty nine brick-and-mortar specialty vape stores in Ontario under the one hundred eighty Smoke Vape Store brand, a dominant national e-commerce platform and three licensed dispensaries in Ontario under the Offside Cannabis brand.
18GF Score
Get the complete analysis for SYDRF
EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SYDRF has been successfully added to your 
